ArticleEuropean heart journal. Digital health2026
Extended reality simulator for dynamic visualization and evaluation of stereotactic arrhythmia radioablation (STAR) treatment plans within RAVENTA trial.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic arrhythmia radioablation (STAR) represents an emerging non-invasive treatment for therapy-refractory ventricular tachycardia. Yet, planning remains challenged by multimodal cardiac imaging integration, electroanatomical mapping (EAM) transfer, and cardiorespiratory motion effects on dose delivery. Current radiotherapy (RT) planning systems offer mainly static visualization and limited access to intramural myocardial structures, hindering communication between cardiology and radiation oncology teams. We present a novel extended reality (XR) simulator designed to dynamically visualize STAR-relevant imaging and planning data. The system integrates diastolic cardiac CT, respiratory-binned 4DCT, anatomical segmentations, EAM data, and phase-recomputed RT dose distributions within an XR environment. Cardiac structures are propagated across respiratory phases using deformable registration, while dose distributions are recomputed on each respiratory-binned CT, enabling phase-specific inspection of dose conformality for both planning target volumes (PTVs) and cardiac target volumes (CardTVs). The resulting time-resolved volumetric dataset is rendered in XR, allowing clinicians to explore cardiac motion, visualize intramural dose deposition, and jointly assess target and organ-at-risk dynamics. This supports qualitative evaluation of dose-motion interplay and interdisciplinary interpretation of intramural targets. The system was tested on three STAR patients enrolled in the RAVENTA trial. Motion analysis revealed PTV centroid displacement amplitudes over the breathing cycle of up to 17.5, 10.2, and 8.9 mm for patients 1, 2, and 3, respectively, with conformity number variations of 0.38, 0.34, and 0.19. Expert evaluation showed positive perceived utility for target-anatomy-dose understanding, motion interpretation, and multidisciplinary communication. This proof-of-concept demonstrates the feasibility and potential clinical value of XR-based motion-aware dose visualization for STAR planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.